Laurus Labs has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported 18.62% rise in its net profit at Rs 121.32 crore for the quarter under review as compared to Rs 102.28 crore for the same quarter in the previous year. Total income of the company increased by 11.93% at Rs 1,438.61 crore for Q4FY24 as compared Rs 1,285.28 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 29.77% fall in its net profit at Rs 75.32 crore for fourth quarter ended March 31, 2024 as compared to Rs 107.24 crore for the same quarter in the previous year. However, total income of the company increased by 5.47% at Rs 1,458.20 crore for Q4FY24 as compared Rs 1382.61 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 70.58% fall in its net profit at Rs 223.70 crore as compared to Rs 760.38 crore for the previous year. Total income of the company decreased by 16.06% at Rs 4,859.81 crore for year under review as compared to Rs 5,789.40 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 78.89% fall in its net profit at Rs 168.21 crore as compared to Rs 796.64 crore for the previous year. Total income of the company decreased by 16.20% at Rs 5,067.17 crore for year under review as compared to Rs 6,046.55 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1841.50 |
Dr. Reddys Lab | 1355.15 |
Cipla | 1489.20 |
Lupin | 2181.60 |
Zydus Lifesciences | 959.55 |
View more.. |